Innate Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	28.09	66.4	70.61	84.23	103.76
Short-Term Investments	6.22	14.37	21.85	17.26	16.08
Cash & Short-Term Investments	34.31	80.77	92.46	101.49	119.84
Cash Growth	-57.52%	-12.64%	-8.90%	-15.31%	-20.97%
Accounts Receivable	12.4	4.97	55.56	38.35	18.42
Total Current Assets	46.71	85.74	148.01	139.83	138.26
Net Property, Plant & Equipment	4.36	5.13	6.32	8.54	10.17
Other Intangible Assets	-	-	0.42	1.56	44.19
Long-Term Investments	10.46	10.28	9.8	35.12	39.88
Other Long-Term Assets	1.2	9.9	10.64	22.82	35
Total Assets	62.72	111.06	175.19	207.86	267.5
Accounts Payable	15.04	16.01	17.02	20.91	28.57
Current Portion of Leases	8.8	8.71	8.94	2.1	30.75
Unearned Revenue	9.33	8.06	13.51	16.78	19.92
Other Current Liabilities	3.48	0.21	0.17	1.54	0.65
Total Current Liabilities	36.65	32.98	39.64	41.34	79.89
Long-Term Leases	13.77	22.29	30.96	40.15	13.5
Other Long-Term Liabilities	34	46.96	52.69	72.23	66.67
Total Long-Term Liabilities	47.77	69.24	83.65	112.37	80.17
Total Liabilities	84.42	102.23	123.29	153.71	160.06
Common Stock	4.69	4.19	4.04	4.01	3.98
Additional Paid-in Capital	408.03	390.98	384.26	379.64	375.22
Accumulated Other Comprehensive Income	1.12	0.03	0.5	0.82	0.46
Retained Earnings	-435.54	-386.36	-336.89	-330.32	-272.21
Shareholders' Equity	-21.7	8.83	51.9	54.15	107.44
Total Liabilities & Equity	62.72	111.06	175.19	207.86	267.5
Total Debt	22.57	31	39.89	42.25	44.25
Net Cash (Debt)	11.74	49.78	52.56	59.23	75.59
Net Cash Growth	-76.42%	-5.30%	-11.26%	-21.63%	-42.98%
Net Cash Per Share	0.13	0.61	0.65	0.74	0.95
Book Value	-21.7	8.83	51.9	54.15	107.44
Book Value Per Share	-0.24	0.11	0.65	0.68	1.35
Tangible Book Value	-21.7	8.83	51.49	52.6	63.25
Tangible Book Value Per Share	-0.24	0.11	0.64	0.66	0.80

SEC Filings: 10-K · 10-Q